Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT +3.11%70 Days Sales Outstanding is 98.49 as of Jun. 2026, which is 51% above its 10-year median of 65.02. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $83.80 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 812 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 77.46% on this metric.
The historical rank and industry rank for PROCEPT BioRobotics's Days Sales Outstanding or its related term are showing as below:
PRCT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.83 Med: 65.02 Max: 107.2
Current: 98
During the past 7 years, PROCEPT BioRobotics's highest Days Sales Outstanding was 107.20. The lowest was 31.83. And the median was 65.02.
PRCT's Days Sales Outstanding is ranked worse than 77.46% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs PRCT: 98.00
PROCEPT BioRobotics's Days Sales Outstanding
increased
from Jun. 2025 (92.24) to Jun. 2026 (98.49).
PROCEPT BioRobotics (NAS:PRCT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PROCEPT BioRobotics Days Sales Outstanding Related Terms
PROCEPT BioRobotics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs INMD, LMRI, QDEL: Days Sales Outstanding Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Days Sales Outstanding falls into.
PROCEPT BioRobotics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Days Sales Outstanding of 98.49 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PROCEPT BioRobotics and its competitors. This is 51% above median its historical median of 65.02. Over the past decade, PROCEPT BioRobotics' Days Sales Outstanding has ranged from 31.83 to 107.20. According to the industry distribution chart, PROCEPT BioRobotics ranks #629 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is PROCEPT BioRobotics' Days Sales Outstanding too high?
PROCEPT BioRobotics' current Days Sales Outstanding of 98.49 is 51% above median its 10-year median of 65.02. Over the past 10 years, this metric has ranged from a low of 31.83 to a high of 107.20. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. PROCEPT BioRobotics' value of 98.49 is 51.1% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #629 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Days Sales Outstanding compare to INMD and LMRI?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #629 out of 812 companies for Days Sales Outstanding. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. PROCEPT BioRobotics' value of 98.49 is 51.1% above this benchmark. Historically, PROCEPT BioRobotics' own Days Sales Outstanding has ranged from 31.83 to 107.20 over the past decade. While the company's 10-year median is 65.02 vs. the industry median of 65.17, PROCEPT BioRobotics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Days Sales Outstanding of 98.49 is 51.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Days Sales Outstanding is 98.49, which is 51% above median its own 10-year median of 65.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.80, compared to a current price of $21.91 — trading 73.9% below its estimated fair value. The current Days Sales Outstanding is 98.49, which is 51% above median its 10-year median of 65.02 and 51.1% above the Medical Devices & Instruments industry median of 65.17. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Days Sales Outstanding is 98.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $21.91 is trading 73.9% below its estimated GF Value™ of $83.80.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Days Sales Outstanding: 98.49 (51% above median its 10-year median of 65.02)
GF Value™: $83.80 vs. price of $21.91 (73.9% below fair value)
Industry Position: 51.1% above the Medical Devices & Instruments median (#629 of 812)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
